Source: Eur Respir J 2003; 21: 842-847
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dik W.A., Versnel M.A., Naber B.A., Janssen D.J., van Kaam A.H., Zimmermann L.J.I.. Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of prematurity. Eur Respir J 2003; 21: 842-847

Member's Comments

No comment yet.

Related content which might interest you: Epidermal growth factor in the lungs of infants developing chronic lung disease Source: Eur Respir J 2001; 18: 796-800 Year: 2001 Decrease of vascular endothelial growth factor in macrophages from long-term smokers Source: Eur Respir J 2005; 25: 626-633 Year: 2005 Insulin-like growth factor-1 in idiopathic pulmonary fibrosis bronchoalveolar lavage fluid protects lung fibroblasts from apoptosis Source: Eur Respir J 2001; 18: Suppl. 33, 358s Year: 2001 Cytokines in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 50S-59S Year: 2001 Increased vascular endothelial growth factor in acute eosinophilic pneumonia Source: Eur Respir J 2003; 21: 774-778 Year: 2003 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis Source: Eur Respir J 2006; 27: 957-963 Year: 2006 HGF and IL-6 in BAL fluid of interstitial lung diseases: effect on human lung fibroblasts Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease Source: Eur Respir J 2006 Oct 01;28(4):824-831 Year: 2006 Studies on hepatocyte growth factor (HGF) in bronchoalveolar lavage (BAL) do not support the concept on its antifibrotic properties in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 An indicative role of serum transforming growth factor-beta 1 (TGF-β1) level on the determination of clinical severity of pulmonary tuberculosis Source: Annual Congress 2005 - Diagnosis of tuberculosis and LTBI Year: 2005 Antifibrotic role of hepatocyte growth factor (HGF) in fibrosing interstial lung diseases Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001 Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Regulation of vascular endothelial growth factor expression in a mouse model of acute respiratory distress syndrome (ARDS) Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Angiogenetic profiles (VEGF and VEGF receptor-1, Flt-1) in bronchoalveolar lavage fluid in patients with interstitial lung diseases Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction Source: Eur Respir J 2012; 40: 424-435 Year: 2012 Down regulation of human insulin-like growth factor in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Hypoxia inducible factor-1? in human emphysema lung tissue Source: Eur Respir J 2011; 37: 775-783 Year: 2011 Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats Source: Eur Respir J 2007; 30: 31-39 Year: 2007 The contribution of transforming growth factor-β and epidermal growth factor signalling to airway remodelling in chronic asthma Source: Eur Respir J 2006; 27: 208-229 Year: 2006